Vertex Pharmaceuticals Incorpor

VRTX

Precision medicineBiotech & pharmaceuticals

$510.08vs prev close▲+6.83(+1.36%)

$402.5852W Range$560.25

68% from low

-4.04 (-0.79%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.09%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -100.0% · Market value -100.0% · Weight -0.09%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.05	SELL	ARKG	1	$460.82	$461
26.03.04	SELL	ARKG	652	$477.89	$311.6K
26.03.03	SELL	ARKG	19,168	$474.27	$9.1M
26.02.27	SELL	ARKG	2,591	$496.83	$1.3M
26.02.25	SELL	ARKG	2,524	$483.05	$1.2M
25.08.12	BUY	ARKG	2,623	$387.77	$1.0M
24.11.06	SELL	ARKG	5,292	$493.64	$2.6M
24.10.25	SELL	ARKG	505	$477.70	$241.2K
24.10.24	SELL	ARKG	5,008	$471.91	$2.4M
24.10.08	SELL	ARKG	566	$458.94	$259.8K
24.10.07	SELL	ARKG	3,553	$448.60	$1.6M
24.09.23	SELL	ARKG	575	$460.00	$264.5K
24.09.12	SELL	ARKG	411	$478.65	$196.7K
24.09.11	SELL	ARKG	2,358	$474.74	$1.1M
24.09.10	SELL	ARKG	2,704	$470.78	$1.3M

03.05SELL

ARKGClose$460.82Est. total$461

03.04SELL

652

ARKGClose$477.89Est. total$311.6K

03.03SELL

19,168

ARKGClose$474.27Est. total$9.1M

02.27SELL

2,591

ARKGClose$496.83Est. total$1.3M

02.25SELL

2,524

ARKGClose$483.05Est. total$1.2M

08.12BUY

2,623

ARKGClose$387.77Est. total$1.0M

11.06SELL

5,292

ARKGClose$493.64Est. total$2.6M

10.25SELL

505

ARKGClose$477.70Est. total$241.2K

10.24SELL

5,008

ARKGClose$471.91Est. total$2.4M

10.08SELL

566

ARKGClose$458.94Est. total$259.8K

10.07SELL

3,553

ARKGClose$448.60Est. total$1.6M

09.23SELL

575

ARKGClose$460.00Est. total$264.5K

09.12SELL

411

ARKGClose$478.65Est. total$196.7K

09.11SELL

2,358

ARKGClose$474.74Est. total$1.1M

09.10SELL

2,704

ARKGClose$470.78Est. total$1.3M

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Ray DalioBridgewater Associates

Decreased

27,488

Portfolio Weight

0.05%

Est. Value

$12M

vs Prev Quarter

-28% (38K→27K)

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

Est. Sold Value

$477.89

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Analyst Targets

avg.

$571.61

vs Current ▲ +12.1% upside

Current$510.08

Low ~ High$350.00 ~ $672.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

RBC Capital

Outperform

$576.00

+12.92%

$503.25

Maintain

2026-10-08

UBS

Buy

$615.00

+20.57%

$527.67

Maintain

2026-09-28

Truist Securities

Buy

$565.00

+10.77%

$484.83

Maintain

2026-08-05

Barclays

Overweight

$617.00

+20.96%

$484.83

Maintain

2026-08-05

TD Cowen

Buy

$550.00

+7.83%

$478.71

Maintain

2026-08-04

1 / 4

Avg Target

$571.61

vs Current ▲ +12.1% upside

Buy

32 analysts

Strong Buy 6Buy 20Hold 5Sell 1

Low $350.00

Current $510.08

High $672.00

Firm	Position	Target	Upside	Close	Action	Date
RBC Capital	Outperform	$576.00	+12.92%	$503.25	Maintain	26.10.08
UBS	Buy	$615.00	+20.57%	$527.67	Maintain	26.09.28
Truist Securities	Buy	$565.00	+10.77%	$484.83	Maintain	26.08.05
Barclays	Overweight	$617.00	+20.96%	$484.83	Maintain	26.08.05
TD Cowen	Buy	$550.00	+7.83%	$478.71	Maintain	26.08.04

1 / 4

Price Information

Previous Close$503.25

Open$502.11

Day Range$502.06 - $514.85

52-Week Range$402.58 - $560.25

1-Year Change25.21%

Trading Volume

Volume1,469,287

Avg Volume (3mo)1,149,471

Valuation

Market Cap129.3B

Book Value$79.92

Shares Outstanding253,460,924

Financials

Revenue (TTM)12.6B

Net Income4.4B

EPS$17.17

EBITDA5.1B

Profitability

P/E Ratio29.71

P/B Ratio6.38

Return on Equity (ROE)23.54%

Return on Assets (ROA)11.93%

Profit Margin35.00%

EV/EBITDA24.20

Beta0.28

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)49.42

Company Overview

Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for serious diseases, primarily cystic fibrosis (CF). Its main products are a suite of CFTR modulators like TRIKAFTA/KAFTRIO, and it is expanding into other areas such as sickle cell disease, kidney disease, and pain management. Vertex holds a leading market position in CF treatments and is actively pursuing a pipeline of innovative therapies.

P/B

6.38

High valuation

ROE

23.5%

High return

Beta

0.28

Low volatility

RSI(14)

49.4

Neutral

AI-generated summary. Not investment advice.

Vertex Pharmaceuticals Incorpor

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks